A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
Latest Information Update: 30 Jul 2020
At a glance
- Drugs Venetoclax (Primary) ; Bendamustine; Rituximab
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 28 Jul 2020 Status changed from active, no longer recruiting to completed.
- 29 Jun 2020 Planned End Date changed from 26 Oct 2020 to 14 Jul 2020.
- 29 Jun 2020 Planned primary completion date changed from 26 Oct 2020 to 14 Jul 2020.